Add this topic to your myFT Digest for news straight to your inbox
Corporate America dismayed by latest government intervention to block takeovers
It becomes the latest Magic Circle firm to change leadership
US group to develop arthritis drug with Belgian biotech firm
UK drugmaker has option to buy remainder of US-Dutch biotech company for about $7bn
Cancer drugs are not certain to ensure the pharma group’s share price recaptures past glories
UK-based group seeking to reinforce research and development pipeline before patents lapse
Outcry over a 5,000% price rise has rattled stocks and hardened opinion for change on pricing models
Speculation over plans for its $17bn cash pile has grown as rivals have consolidated
New kind of copycat drugs pose threat to big pharma
Push for deals increases in spite of White House crackdown on controversial foreign takeovers
The threat of a flood of generic drugs sparks a spending spree
‘Immunotherapy’ treatments turn the body’s immune system into a weapon against disease
Taxes and tepid economy stop companies from repatriating dollars
Global record comes as industry prepares to launch new treatments that could add to costs
As big pharma bets huge sums on the next breakthrough drugs, some investors fear another bubble
The market’s view on the impact of biosimilars is sanguine, but this may be wrong
‘Eat or be eaten’ mindset to drive more deals as groups try to replace sales lost when patents expire
AbbVie $21bn bid delivers almost $4bn to executives
How AbbVie came out on top in pharma’s most competitive auction
Latest wave of deals has targeted biotechs in a bid to replenish R&D pipelines as patents expire
Value of healthcare deals in past 15 months reaches nearly $500bn
Investment bank builds on consumer products role
Big Pharma’s cost of doing business is rising. So are share prices. Can this go on?
International Edition